Good for you Craig… that you can keep the door open for
Good for you Craig… that you can keep the door open for the 13d group. I am way past all the misinformation and out right lies that have been pushed by the bashers who I believe are more than just average stock holders. I am sure we have many paid basher pushing their agenda not just here but on all social media and chat boards. This is a big production that they have tried to accomplish. I feel that they were coarse and abrasive and just didn’t function in a way that garnered enough support. I think they have failed in their bid to take over the company. This proxy card that I don’t remember the color of will let them know in a day or so that they have ultimately failed.
This deception and effort of the 13d group doesn’t bode well. It just wont matter what the can provide as a plan for me now that I would even consider changing sides. It’s just to late for them to bring something to the table that would be worthy. They have shown their true colors and honesty isn’t one attribute they have. They just don’t have anything I would be excited about. Their leadership from top to bottom isn’t impressive and lack any experience needed in a biotech. Last I checked we are a biotech and the 13d people that might have some experience were former employees that sued us and cost us millions. Just the wrong type of people to put forward as someone we need or want. Are these former employees looking for revenge?
I feel that the 13d group has put hate as their number one priority to inflict on our company and that’s just not ok. It’s not ok to push a bashing agenda and be rewarded with followers. People are not fooled by such terrible actions. Nobody aspires to be a basher and hopes to be liked for it. We can’t take a chance on an inexperienced new management that is clueless to everything going on with partnerships and relationships with people all over the world and will take many months to get up to speed figure it all out. Now is not the time to allow a new group to take the reins on a company on the cusp of great things.
There is so many positive catalysts happening in the next few months. I feel fortunate to be invested in this company and see the growth of this management to learn the lessons they have and apply the knowledge to the new trials. We are almost there and don’t need any help to get there. Especially from a group I wouldn’t trust them as far as I could throw them.
Everyone should really ask themselves who is more trust worthy? A management with a plan to trial 10 indications a year and grow into our own big Pharma or a group that doesn’t have a plan. Won’t show us a plan and never had a plan they would ever show us. It’s really quite scary and not very genuine to believe someone that has no apparent leadership or direction to show us something now. Our management has been straight forward and left no doubt in their plan or their new presentation. I approve of our current direction and future direction and see great things happening. Why take a chance on a group that could screw us over. That just doesn’t make sense. I won’t trust someone like the 13d group with my money. They have done nothing to impress us or do we expect them to. The big issue here is trust… who has earned my trust. I can tell you I have absolutely no trust in the 13d group.
16
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....
Continue Reading
AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...
Continue Reading
A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...
Continue Reading
Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...
Continue Reading
A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...
Continue Reading
Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...
Continue Reading
Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...
Continue Reading
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...
Continue Reading
When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...
Continue Reading
Top 5 Most Recently Viewed Articles
Exciting Development in Mental Health Treatment In a groundbreaking collaboration, BioXcel Therapeutics, Inc. (NASDAQ: BTAI) has joined forces with the University of North Carolina at Chapel Hill (UNC) thanks to a substantial grant from the U.S. Department of Defense. This grant aims to explore the effectiveness and safety of BXCL501, a novel treatment for acute stress...
Continue Reading
Alumni Champions of Environmental Research In a remarkable tale of collaboration fueled by a shared passion for wildlife research, Eastern Michigan University alumni Dorothy Zahor and Kenneth Glynn came together to explore environmental issues through the lens of urban wildlife. Their dedication to the study of American robins has revealed fascinating insights into how...
Continue Reading
Verkada Strengthens Global Channel Operations Verkada, known for its innovative cloud-based physical security solutions, recently announced a strategic enhancement in its global channel operations with the appointment of Micah Deriso as Head of Global Channel. This strategic move aims to bolster Verkada's global partnerships and streamline its channel strategy. Meet Micah...
Continue Reading
Purcell & Lefkowitz LLP Investigates Citi Trends, Inc. Recently, Purcell & Lefkowitz LLP announced an investigation concerning Citi Trends, Inc. (NASDAQ: CTRN). This inquiry arises from concerns regarding the fiduciary duties of the directors amidst ongoing corporate actions. The aim is to determine if there have been any breaches that may affect shareholders....
Continue Reading
Prairie Operating Co. Announces Successful Shelduck South Pad Completion Prairie Operating Co. (Nasdaq: PROP) has recently achieved a remarkable milestone with the timely completion of its Shelduck South pad in the DJ Basin. This accomplishment marks the successful culmination of the first phase of its development program for 2025, aiming for all production to be fully...
Continue Reading